Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

Open access
Daugla, DM, Gami, JP, Gamougam, K, Naibei, N, Mbainadji, L, Narbé, M, Toralta, J, Kodbesse, B, Ngadoua, C, Coldiron, ME, Fermon, F, Page, A-L, Djingarey, MH, Hugonnet, S, Harrison, OB, Rebbetts, LS, Tekletsion, Y, Watkins, ER, Hill, D, Caugant, DA, Chandramohan, D, Hassan-King, M, Manigart, O, Nascimento, M, Woukeu, A, Trotter, C, Stuart, JM, Maiden, MCJ, Greenwood, BM·2014·The Lancet

Abstract

BACKGROUND: A serogroup A meningococcal polysaccharide-tetanus toxoid conjugate vaccine (PsA-TT, MenAfriVac) was licensed in India in 2009, and pre-qualified by WHO in 2010, on the basis of its safety and immunogenicity. This vaccine is now being deployed across the African meningitis belt. We studied the effect of PsA-TT on meningococcal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic. METHODS: We obtained data for the incidence of meningitis before and after vaccination from national records between January, 2009, and June, 2012. In 2012, surveillance was enhanced in regions where vaccination with PsA-TT had been undertaken in 2011, and in one district where a reactive vaccination campaign in response to an outbreak of meningitis was undertaken. Meningococcal carriage was studied in an age-stratified sample of residents aged 1-29 years of a rural area roughly 13-15 and 2-4 months before and 4-6 months after vaccination. Meningococci obtained from cerebrospinal fluid or oropharyngeal swabs were characterised by conventional microbiological and molecular methods. FINDINGS: Roughly 1·8 million individuals aged 1-29 years received one dose of PsA-TT during a vaccination campaign in three regions of Chad in and around the capital N'Djamena during 10 days in December, 2011. The incidence of meningitis during the 2012 meningitis season in these three regions was 2·48 per 100,000 (57 cases in the 2·3 million population), whereas in regions without mass vaccination, incidence was 43·8 per 100,000 (3809 cases per 8·7 million population), a 94% difference in crude incidence (p<0·0001), and an incidence rate ratio of 0·096 (95% CI 0·046-0·198). Despite enhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the three vaccinated regions. 32 serogroup A carriers were identified in 4278 age-stratified individuals (0·75%) living in a rural area near the capital 2-4 months before vaccination, whereas only one serogroup A meningococcus was isolated in 5001 people living in the same community 4-6 months after vaccination (adjusted odds ratio 0·019, 95% CI 0·002-0·138; p<0·0001). INTERPRETATION: PSA-TT was highly effective at prevention of serogroup A invasive meningococcal disease and carriage in Chad. How long this protection will persist needs to be established. FUNDING: The Bill & Melinda Gates Foundation, the Wellcome Trust, and Médecins Sans Frontères.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)61612-8

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 16

  1. Lapeyssonie, 1963, The meningococcal meningitis in Africa, Bull World Health Org, 28, 3
  2. Ledentu, 1941, Cerebrospinal meningitis in French Equatorial Africa during the first half of 1939, Bull Off Int d'Hyg Publ, 3, 421
  3. Sirol, 1969, Some new aspects of purulent meningitis in Sahelian Africa. Clinical, bacteriological and therapeutic study of 368 cases observed in 1969 at Fort-Lamy (Tchad), Med Tropicale, 29, 443
  4. Garcia, 2004, Outbreak of meningitis in the province of Logone occidental (Chad): descriptive study using health ministry data from 1998 to 2001, Bull Soc Path Exot, 97, 183
  5. Bregani, 2006, The 2001 meningitis epidemic in south Chad, Minerva Med, 97, 161
  6. 2010, Meningitis in Chad, Niger, and Nigeria: 2009 epidemic season, Wkly Epidemiol Rec, 8, 57
  7. Riou, 1996, A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995, Bull World Health Org, 74, 181
  8. Caugant, 2012, Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine, PLoS One, 7, e46019, 10.1371/journal.pone.0046019 · doi:10.1371/journal.pone.0046019
  9. Labrie, 2010, Whole cell vaccines for the meningococcus: lessons from an idea for which time has gone, Hum Vaccin, 6, 360, 10.4161/hv.6.4.11055 · doi:10.4161/hv.6.4.11055
  10. Spiegel, 1993, Effect of 2 vaccination strategies on developments during the epidemic of meningococcal A meningitis in N'Djamena (Chad) in 1988, Bull World Health Org, 71, 311
  11. Lengeler, 1995, The 1990 meningococcal meningitis epidemic of Sarh (Chad): how useful was an earlier mass vaccination, Acta Tropica, 59, 211, 10.1016/0001-706X(95)00081-O · doi:10.1016/0001-706x(95)00081-o
  12. Massenet, 2011, Epidemic meningococcal meningitis, Cameroon, Emerg Infect Dis, 17, 2002, 10.3201/eid1711.110468 · doi:10.3201/eid1711.110468
  13. Suker, 1994, The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation, Mol Microbiol, 12, 253, 10.1111/j.1365-2958.1994.tb01014.x · doi:10.1111/j.1365-2958.1994.tb01014.x
  14. Kim, 2012, Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010, PLoS One, 7, e29116, 10.1371/journal.pone.0029116 · doi:10.1371/journal.pone.0029116
  15. Caini, 2013, From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010–January 2012, Vaccine, 31, 1597, 10.1016/j.vaccine.2013.01.015 · doi:10.1016/j.vaccine.2013.01.015
  16. Altmann, 2013, Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt, Vaccine, 31, 1453, 10.1016/j.vaccine.2012.12.035 · doi:10.1016/j.vaccine.2012.12.035

Cited by

See all 256

Metadata

Authors
Daugla, D., Gami, J., Gamougam, K., Naibei, N., Mbainadji, L., Narbé, M., Toralta, J., Kodbesse, B., Ngadoua, C., Coldiron, M., Fermon, F., Page, A.-L., Djingarey, M., Hugonnet, S., Harrison, O., Rebbetts, L., Tekletsion, Y., Watkins, E., Hill, D., Caugant, D., Chandramohan, D., Hassan-King, M., Manigart, O., Nascimento, M., Woukeu, A., Trotter, C., Stuart, J., Maiden, M., & Greenwood, B.
Venue
The Lancet
Publisher
Elsevier BV
Published
2014-01
Volume
383
Issue
9911
Pages
40-47
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2047179190
Cited by
256
References
14
FWCI
30.69
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. https://app.cochat.ai/papers/10.1016/s0140-6736(13)61612-8
The paper
Daugla, D., Gami, J., Gamougam, K., Naibei, N., Mbainadji, L., Narbé, M., Toralta, J., Kodbesse, B., Ngadoua, C., Coldiron, M., Fermon, F., Page, A.-L., Djingarey, M., Hugonnet, S., Harrison, O., Rebbetts, L., Tekletsion, Y., Watkins, E., Hill, D., . . . Greenwood, B. (2014). Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. The Lancet. https://doi.org/10.1016/s0140-6736(13)61612-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.